Neurogene Inc. NGNE 深 滬
已收盤 02-06 16:00:00 美东时间
17.23
+0.860
+5.25%
華盛通- 最 高17.46
- 今 開16.87
- 成交量 9.12万股
- 最 低 16.30
- 昨 收 16.37
- 總市值 2.67亿
- 52周最高 37.2659
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 6.875
- 委 比 13.04%
- 總股本 1548.98万
- 歷史最高 362.60
- 量 比 0.61
- 振 幅 7.09%
- 歷史最低 6.875
- 每 手 1
- 風險率 4.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
LifeSci Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $50
LifeSci Capital analyst Patrick Dolezal initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $50.
01-26 21:45
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $70 price target.
01-13 20:20
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Trial Evaluating NGN-401 Demonstrates All 8 Patients Showed Functional Gains Across Spectrum Of Disease Severity
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical
2025-11-13 05:13
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
2025-11-05 03:25
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
2025-11-03 20:20
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $45 to $65.
2025-10-31 18:58
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
2025-10-10 11:36
